| |
OS
|
RFS
|
|---|
|
Pancreatobiliary type
|
HR (95% CI)
|
n (events)
|
p†
|
HR (95% CI)
|
n (events)
|
p†
|
|---|
|
All cases
| | | | | | |
|
SATB1 neg
|
1.00
|
84 (63)
| |
1.00
|
84 (69)
| |
|
SATB1 pos
|
2.11 (1.25-3.56)
|
21 (19)
| |
1.87 (1.10-3.18)
|
21 (18)
| |
|
No adjuvant treatment
| | |
0.166
| | |
0.927
|
|
SATB1 neg
|
1.00
|
40 (30)
|
1.00
|
40 (33)
|
|
SATB1 pos
|
2.94 (1.37-6.29)
|
9 (9)
|
1.63 (0.71-3.74)
|
9 (7)
|
|
Any adjuvant treatment
| | | | |
|
SATB1 neg
|
1.00
|
44 (33)
|
1.00
|
44 (36)
|
|
SATB1 pos
|
1.70 (0.83-3.52)
|
12 (10)
|
2.05 (1.02-4.11)
|
12 (11)
|
|
No gemcitabine
| | |
0.066
| | |
0.384
|
|
SATB1 neg
|
1.00
|
46 (35)
|
1.00
|
46 (38)
|
|
SATB1 pos
|
3.14 (1.60-6.16)
|
12 (12)
|
2.05 (1.00-4.20)
|
12 (10)
|
|
Gemcitabine
| | | | |
|
SATB1 neg
|
1.00
|
38 (28)
|
1.00
|
38 (31)
|
|
SATB1 pos
|
1.44 (0.62-3.35)
|
9 (7)
|
1.60 (0.72-3.56)
|
9 (8)
|
|
Intestinal type
| | | | | | |
|
All cases
| | | | | | |
|
SATB1 neg
|
1.00
|
45 (22)
| |
1.00
|
45 (20)
| |
|
SATB1 pos
|
1.06 (0.47-2.38)
|
16 (8)
| |
1.26 (0.57-2.77)
|
16 (9)
| |
|
No adjuvant treatment
| | |
0.165
| | |
0.021
|
|
SATB1 neg
|
1.00
|
33 (17)
|
1.00
|
33 (13)
|
|
SATB1 pos
|
1.62 (0.67-3.92)
|
10 (7)
|
2.69 (1.11-6.51)
|
10 (8)
|
|
Any adjuvant treatment
| | | | |
|
SATB1 neg
|
1.00
|
12 (5)
|
1.00
|
12 (7)
|
|
SATB1 pos
|
0.30 (0.03-2.56)
|
6 (1)
|
0.18 (0.02-1.46)
|
6 (1)
|
|
No gemcitabine
| | |
0.649
| | |
0.143
|
|
SATB1 neg
|
1.00
|
40 (20)
|
1.00
|
40 (17)
|
|
SATB1 pos
|
1.20 (0.51-2.83)
|
12 (7)
|
1.76 (0.76-4.09)
|
12 (8)
|
|
Gemcitabine
| | | | |
|
SATB1 neg
|
1.00
|
5 (2)
|
1.00
|
5 (3)
|
|
SATB1 pos
|
0.67 (0.06-7.53)
|
4 (1)
|
0.27 (0.03-2.64)
|
4 (1)
|
-
†P value for term of interaction by Cox multivariable analysis including treatment, SATB1 expression, gemcitabine vs no gemcitabine or any adjuvant vs no adjuvant, and a term of interaction. Bold text indicates significant values.
